Is InMed Pharmaceuticals Inc (INM) overvalued? · rev $4.9M
InMed Pharmaceuticals Inc (INM) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether InMed Pharmaceuticals Inc (INM) looks expensive on cached numbers — not a short thesis.
Latest reported INM revenue for 2025-06-30 was $4.9M. Net income was -$8.2M. INM currently screens at market cap $5.2M.
INM currently screens at market cap $5.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next INM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the INM stock page for the full model, not this heading.
Not investment advice.